A Rare Case Report of Uterine Carcinosarcoma in Patient with History of Breast Carcinoma
DOI:
https://doi.org/10.21276/apalm.3672Keywords:
carcinosarcomas, Postmenopausal female, Abnormal uterine bleeding, Breast CarcinomaAbstract
Uterine carcinosarcoma (UCS), or malignant mixed Müllerian tumor, is a rare and aggressive uterine malignancy comprising malignant epithelial and mesenchymal components. We present the case of a 67-year-old postmenopausal woman with abdominal pain and anemia, and a history of breast carcinoma. Initial imaging suggested an endometrial polyp; biopsy was inconclusive. Persistent symptoms led to hysterectomy with bilateral salpingo-oophorectomy. Grossly, the uterus contained a bulky grey-white tumor (7x5x3 cm). Histopathology revealed serous adenocarcinoma (CK, p53 positive; ER negative) admixed with vimentin-positive homologous sarcoma, with >50% myometrial invasion; adnexa were uninvolved (FIGO stage IA). UCS has a poor prognosis and is occasionally linked to prior tamoxifen use, though hormonal therapy history was unavailable in this patient. This case highlights the need for suspicion of UCS in postmenopausal women with uterine masses and prior breast carcinoma, even without confirmed tamoxifen exposure. Early recognition and histopathologic confirmation are vital to guide management in this aggressive malignancy.
References
1. Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 2009:7:550-6.
2. Ho SP, Ho TH. Malignant mixed Mullerian tumours of the uterus: a ten-year experience. Singapore Med J 2002:43:452-6.
3. Friedrich M, Villena-Heinsen C, Mink D, Bonkhoff H, Schmidt W. Carcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer. Eur J Obstet Gynecol Reprod Biol 1999:82:85-7.
4. Fotiou S, Hatjieleftheriou G, Kyrousis G, Kokka F, Apostolikas N. Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res 2000:20:2015-20.
5. McCluggage WG, Abdulkader M, Price JH, Kelehan P, Hamilton S, Beattie J, et al. Uterine carcinosarcomas in patients receiving tamoxifen: a report of 19 cases. Int J Gynecol Cancer 2000;10:280-4.
6. Kloos I. Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer 2002;12:496-500.
7. Hubalek M, Ramoni A, Mueller-Holzner E, Marth C. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. Gynecol Oncol 2004:95:264-6.
8. Yildirim Y, Inal MM, Sanci M, Yildirim YK. Mit T, Polat M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer 2005;15:1239-42.
9. Arenas M, Rovirosa A, Hernandez V, Ordi J, Jorcano S, Mellado B, et al. Uterine sarcomas in breast cancer patients treated with tamoxifen. Int J Gynecol Cancer 2006;16:861-5.
10. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004:96:70-4.
11. Rieck GC, Freites ON, Williams S. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol 2005:25:39-41.
12. Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005 97:375-84.
13. Saadat M, Truong PT, Kader HA, Speers CH, Berthelet E, McMurtrie E, et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer 2007;110:31-7.
14. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 1997;236:140-5.
15. Zafrakas M, Kostopoulou E, Dragoumis K, Mikos T, Papadimas J, Bontis J. Expression of estrogen receptors alpha and beta in two uterine mesenchymal tumors after prolonged tamoxifen therapy: report of two cases. Eur J Gynaecol Oncol 2004:25:530-3.
16. Raspollini MR, Mecacci F, Paglierani M, Marchionni M, Taddei GL. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. Pathol Res Pract 2005;201:141-4.
17. Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, et al. ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol 2004;95:583-7.
18. Marques MM, Beland FA. Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis 1997:18:1949-54.
19. Martin EA, Brown K, Gaskell M, Al-Azzawi F. Garner RC, Boocock DJ, et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 2003:63:8461-5.
20. Slomovitz BM, Sun CC, Ramirez PT, et al. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2004;104:255Y260.
21. Gonzalez Bosquet J. Terstriep SA, Cliby WA et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010;116:419-423.
22. Gorai 1, Yanagibashi T, Taki A et al. Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer. 1997:72:821-827.
23. Williamson EO, Christopherson WM. Malignant mixed mullerian tumors of the uterus. Cancer. 1972:29:585-592. doi: 10.1002/1097-0142(197203)29:31585::AID-CNCR282029030923.0.CO;2-1.
24. Sebenik M, Yan Z. Khalbuss WE, Mittal K. Malignant mixed mullerian tumor of the vagina: Case report with review of the literature, immunohistochemical study and evaluation for human papilloma virus. Hum Pathol. 2007:38:1282-1288. doi: 10.1016/j.humpath.2007.03.008.
25. Jin Z, Ogata S, Tamura G. Katayama Y, Fukase M, Yajima M, et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: A genetic study with special reference to histogenesis. Int J Gynecol Pathol. 2003:22:368-373.
26. Spaziani E, Picchio M, Petrozza V, Briganti M, Ceci F. Di Filippo A, et al. Carcinosarcoma of the uterus: A case report and review of the literature. Eur J Gynaecol Oncol. 2008;29:531-34.
27. Macasaet MA, Waxman M, Fruchter RG, Boyce J, Hong P, Nicastri AD, et al. Prognostic factors in malignant mesodermal (mullerian) mixed tumors of the uterus. Gynecol Oncol. 1985:20:32-42.
28. Gallup DG, Gable DS, Talledo OE, Otken LB., Jr A clinical-pathologic study of mixed mullerian tumors of the uterus over a 16-year period-the medical college of georgia experience. Am J Obstet Gynecol. 1989;161:533-538. doi: 10.1016/0002-9378(89)90352-9.
29. Ali S. Wells M. Mixed mullerian tumors of the uterine corpus: A review. Int J Gynecol Cancer. 1993;3:1-11. doi: 10.1046/j.1525-1438.1993.03010001.x.
30. Villena-Heinsen C. Diesing D, Fischer D, Griesinger G, Maas N, Diedrich K, et al. Carcinosarcomas a retrospective analysis of 21 patients. Anticancer Res. 2006 26:4817-4823.
31. Norris HJ, Roth E, Taylor HB. Mesenchymal tumors of the uterus. II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol. 1966;28:57-63.
32. Rauh-Hain JA, Shoni M, Schorge JO, Goodman A, Horowitz NS, del Carmen MG. Prognostic determinants in patients with uterine and ovarian carcinosarcoma. J Reprod Med. 2013;58:297-304.
33. Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, Tinar S. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1239-42. doi: 10.1111/j.1525-1438.2005.00170.x. PMID: 16343223.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Meenu Gill, Mahak Dahiya, Biswasree Deb, Promil Jain, Geetika, Sunita Singh
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
